Try The Drug Club risk-free for 30 days Trial terms

Tacrolimus Topical — Membership Pricing

Tacrolimus Topical is not confirmed for no-additional-cost pricing. Membership pricing may be available; confirm the price with the dispensing pharmacy.

Tacrolimus Topical Pricing

Pricing typePrice
TheDrugClubMembership pricing may be available
Typical Retail$112.00

Membership pricing may be available; confirm the price with the dispensing pharmacy.

About Tacrolimus Topical

Tacrolimus Topical is a prescription medication. Ask your doctor if Tacrolimus Topical is right for you.

Other strengths and forms of Tacrolimus

How to Check Tacrolimus Topical Pricing

  1. Join TheDrugClub for $19.95/month
  2. Receive your member card by email
  3. Present your card at a participating pharmacy
  4. Check active-formulary eligibility or available membership pricing

Tacrolimus Topical at Participating Pharmacies

Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.

Other medications in Dermatology

About Tacrolimus Topical

Tacrolimus topical is a prescription medication commonly used to treat moderate to severe atopic dermatitis (eczema) in adults and children. If you've been prescribed this powerful anti-inflammatory, you know that managing the cost can be a concern. TheDrugClub is dedicated to helping members like you find significant savings on essential medications, including tacrolimus topical.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Tacrolimus Topical is approved for (FDA label)

Tacrolimus ointment, both 0.03% and 0.1% for adults, and only 0.03% for children aged 2 to 15 years, is indicated as second-line therapy for the short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis in non-immunocompromised adults and children who have failed to respond adequately to other topical prescription treatments for atopic dermatitis, or when those treatments are not advisable. Tacrolimus ointment is not indicated for children younger than 2 years of age (see boxed WARNING, WARNINGS and PRECAUTIONS: Pediatric Use).

Source: Read the full FDA label on DailyMed. Label effective date: April 15, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Tacrolimus Topical (FDA label)

No phototoxicity and no photoallergenicity were detected in clinical studies with 12 and 216 normal volunteers, respectively. One out of 198 normal volunteers showed evidence of sensitization in a contact sensitization study. In three 12 week randomized vehicle-controlled studies and four safety studies, 655 and 9,163 patients respectively, were treated with tacrolimus ointment. The duration of follow-up for adult and pediatric patients in the safety studies is tabulated below.

Source: FDA prescribing information (DailyMed). Set ID: c2d2e3a1-f346-4245-b445-6dd44e371180. SPL document ID: 15dcd504-ee3e-4f0f-a765-55e31511641e. Label effective date: April 15, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Tacrolimus Topical (FDA label)

Tacrolimus ointment is contraindicated in patients with a history of hypersensitivity to tacrolimus or any other component of the ointment.

Source: FDA prescribing information (DailyMed). Set ID: c2d2e3a1-f346-4245-b445-6dd44e371180. SPL document ID: 15dcd504-ee3e-4f0f-a765-55e31511641e. Label effective date: April 15, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Tacrolimus Topical (FDA label)

Formal topical drug interaction studies with tacrolimus ointment have not been conducted. Based on its extent of absorption, interactions of tacrolimus ointment with systemically administered drugs are unlikely to occur but cannot be ruled out (see CLINICAL PHARMACOLOGY ). The concomitant administration of known CYP3A4 inhibitors in patients with widespread and/or erythrodermic disease should be done with caution. Some examples of such drugs are erythromycin, itraconazole, ketoconazole, fluconazole, calcium channel blockers and cimetidine.

Source: FDA prescribing information (DailyMed). Set ID: c2d2e3a1-f346-4245-b445-6dd44e371180. SPL document ID: 15dcd504-ee3e-4f0f-a765-55e31511641e. Label effective date: April 15, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Start Your Risk-Free Trial
Start Your Risk-Free Trial